Journal Article

Camrelizumab Combined with Gemcitabine and Albumin-Bound Paclitaxel in Pancreatic Cancer Patients with Liver Metastases: A Prospective, Pilot Trial

Zhang, Jiandong, Zhang, Yizhou, Jiang, Guixing, Ding, Ying, Hong, Defei, Liu, Xiaolong, Zhao, Kai, Zhou, Weihang, Dong, Xinyu

2026

Overview

Jiandong Zhang,1,* Kai Zhao,1,* Weihang Zhou,1 Guixing Jiang,1 Ying Ding,2 Yizhuo Zhang,1 Xinyu Dong,1 Defei Hong,1 Xiaolong Liu1 1Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 2Department of Intensive Care Unit, Sir Run Run Shaw Hospital Qiantang Campus, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiaolong Liu, Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Shangcheng District, Hangzhou, 310020, People’s Republic of China, Tel [phone], Email [e-mail] Defei Hong, Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Shangcheng District, Hangzhou, 310020, People’s Republic of China, Email [e-mail]: Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors, with approximately 80% of PDAC patients having locally advanced or metastatic disease at diagnosis. The liver is a predominant site of metastasis and is linked to a particularly poor prognosis. Here, we explored camrelizumab (an anti-programmed cell death-1 antibody) combined with albumin-bound paclitaxel and gemcitabine (AG) in patients with PDAC and liver metastases (PCLM).Methods: In this pilot trial (ChiCTR2000038587), patients received camrelizumab (200 mg on day 1) plus gemcitabine (1000 mg/m2 on days 1 and 8) and albumin-bound paclitaxel (125 mg/m2 on days 1 and 8) every 21-day cycle until disease progression, intolerable toxicity, or death. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. Exploratory analyses evaluated potential biomarkers associated with survival.Results: From October 2018 to October 2023, 17 patients were enrolled. The median OS was 14.0 months (95% confidence interval [CI], 10.0– 24.0) and the median PFS was 6.4 months (95% CI, 5.2– 10.2). Five patients achieved an objective response (29.4%), with a DCR of 64.7%. Fewer liver metastasis lesions, higher white blood cell-to-lymphocyte ratio, and lower neutrophil-to-lymphocyte ratio were associated with improved PFS and OS (P< 0.05). Grade 3 treatment-related adverse events (TRAEs) included platelet count decreased (2 [11.8%]) and neutrophil count decreased (1 [5.9%]). No grade 4 or 5 TRAEs occurred.Conclusion: Camrelizumab combined with AG demonstrates promising antitumor activity in patients with PCLM, with an acceptable safety profile.Keywords: camrelizumab, chemotherapy, pancreatic ductal adenocarcinoma, liver metastases

• Publisher: Dove Medical Press
• Subject: camrelizumab / chemotherapy / liver metastases / pancreatic ductal adenocarcinoma